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depressant and placebo arms (9.6 vs. 9.9%). The majority of 
suicides and suicide attempts originated from 1 study, ac-
counting for a fifth of all patient-years in this meta-analysis. 
Leaving out this study resulted in a nonsignificant incidence 
rate ratio for suicide attempts of 3.83 (0.53–91.01).  Conclu-
sions: Therapists should be aware of the lack of proof from 
RCTs that antidepressants prevent suicides and suicide at-
tempts. We cannot conclude with certainty whether antide-
pressants increase the risk for suicide or suicide attempts. 
Researchers must report all suicides and suicide attempts in 
RCTs.  © 2016 S. Karger AG, Basel 
 Introduction 
 In the long run, a considerable number of patients with 
depressive disorders die of suicide. In the Zurich cohort 
of initially hospitalized patients, roughly 15% of individu-
als with major depressive disorder had committed suicide 
after 50 years  [1] . Over the same period of time, the risk 
 Key Words 
 Suicide · Suicide attempt · Suicidality · Antidepressants · 
RCT · Maintenance 
 Abstract 
 Background: It is unclear whether antidepressants can pre-
vent suicides or suicide attempts, particularly during long-
term use.  Methods: We carried out a comprehensive review 
of long-term studies of antidepressants (relapse prevention). 
Sources were obtained from 5 review articles and by search-
es of MEDLINE, PubMed Central and a hand search of bibli-
ographies. We meta-analyzed placebo-controlled antide-
pressant RCTs of at least 3 months’ duration and calculated 
suicide and suicide attempt incidence rates, incidence rate 
ratios and Peto odds ratios (ORs).  Results: Out of 807 studies 
screened 29 were included, covering 6,934 patients (5,529 
patient-years). In total, 1.45 suicides and 2.76 suicide at-
tempts per 1,000 patient-years were reported. Seven out of 
8 suicides and 13 out of 14 suicide attempts occurred in an-
tidepressant arms, resulting in incidence rate ratios of 5.03 
(0.78–114.1; p = 0.102) for suicides and of 9.02 (1.58–193.6;
p = 0.007) for suicide attempts. Peto ORs were 2.6 (0.6–11.2; 
nonsignificant) and 3.4 (1.1–11.0; p = 0.04), respectively. 
Dropouts due to unknown reasons were similar in the anti-
 Received: July 23, 2015 
 Accepted after revision: November 6, 2015 
 Published online: April 5, 2016 
 Christopher Baethge, MD, Professor of Psychiatry 
 Abteilung für Psychiatrie und Psychotherapie 
 Universitätsklinikum Köln 
 Kerpener Str. 62, DE–50937 Köln (Germany) 
 E-Mail cbaethge   @   uni-koeln.de 
 © 2016 S. Karger AG, Basel
0033–3190/16/0853–0171$39.50/0 
 www.karger.com/pps 
 The results of this study were presented at the 29th IGSLi Conference 
in Aalborg, Denmark, in September, 2015. 
D
ow
nl
oa
de
d 
by
: 
S
LU
B
 D
re
sd
en
   
   
   
   
   
   
 
19
4.
95
.1
43
.1
36
 -
 4
/1
6/
20
20
 8
:2
3:
15
 A
M
 Braun/Bschor/Franklin/Baethge
 
 Psychother Psychosom 2016;85:171–179 
DOI: 10.1159/000442293
172
of completed suicide in a Swedish community sample of 
patients with depression averaged approximately 6%, 
whereas the risk amounted to 14% in the subgroup of pa-
tients with severe major depressive disorder  [2] . In a 
model based on 27 studies on mortality in affective disor-
ders, Inskip et al.  [3] estimated the lifetime risk of suicide 
to be 6%. Suicidal acts mostly occur during acute illness 
episodes and in the beginning of the disorder  [4] .
 Although the debate continues about their effect size, 
antidepressants have repeatedly been shown to be effec-
tive psychotropic agents in depression [for overviews, see 
 5, 6 ]. It is hoped, therefore, that antidepressants also re-
duce the risk of suicide. In this sense, the European Psy-
chiatric Association, in their ‘guidance on suicide treat-
ment and prevention’, state that antidepressants decrease 
suicidality  [7] .
 Unfortunately, data regarding the effect of antidepres-
sants on suicidality are inconclusive. In depressed pa-
tients undergoing antidepressant maintenance therapy, 
Angst et al.  [8] reported a statistically significantly lower 
suicide rate relative to untreated patients. In the same 
vein, other authors concluded from epidemiological and 
observational data that antidepressant use lowers the risk 
of suicide  [7, 9, 10] . However, even a positive association 
of antidepressant prescription and suicide rate has been 
reported  [11] . Epidemiological and observational studies, 
however, are vulnerable to confounding bias. This disad-
vantage seems especially relevant for suicide and suicide 
attempts. The complexity of this behavior is illustrated by 
the difficulties in predicting suicides and suicide attempts 
with sufficient certainty – despite a host of risk factors 
that have been published  [12–15] . For an overview of 
methodological difficulties in suicide research, see the 
study by de Leon et al.  [16] .
 Suicidal behavior is often not a stated outcome mea-
sure in antidepressant studies, and these studies are not 
designed for comparing suicide rates. Nevertheless, ran-
domized trials of antidepressant pharmacotherapy lend 
themselves to analyses with regard to suicidality. For ex-
ample, Gibbons et al.  [17] report that fluoxetine and ven-
lafaxine reduce suicidality, as measured primarily by us-
ing suicidality items on rating scales (HMA-D, CDRS-R). 
This is an indirect measurement considering that suicid-
al thoughts constitute the most part of what is considered 
suicidality in this analysis and that they are only weak 
predictors of completed suicides. However, completed 
suicides and suicide attempts matter most to patients. In-
terestingly, other authors did not find a beneficial effect 
of antidepressants on suicide in placebo-controlled acute 
treatment trials  [18–24] . In addition, Storosum et al.  [24] 
presented raw numbers of suicide and suicide attempts 
from several randomized long-term studies and conclud-
ed that their frequency was not higher in placebo groups.
 Long-term studies of depressive disorders are of par-
ticular interest because many depressive disorders take a 
chronic course. It may also be hypothesized that an anti-
suicidal effect of antidepressants is more pronounced in 
long-term treatment because the placebo effect decreases 
and the effect size of antidepressants is relatively high. 
However, there is no comprehensive review of suicides 
and suicide attempts in randomized long-term antide-
pressant studies. As a consequence, we carried out a com-
prehensive review and meta-analysis of placebo-con-
trolled long-term studies. The analysis accounts for dif-
ferent exposure times, sample sizes and dropout rates in 
antidepressant and placebo arms.
 Methods 
 This is a literature review and meta-analysis on suicide and sui-
cide attempts in placebo-controlled randomized trials of long-
term treatment of major depressive disorder with antidepressants.
 Literature Search 
 The initial search was based on 5 reviews on antidepressant 
long-term treatment, three systematic reviews and meta-analyses 
 [25–27] and two narrative reviews  [24, 28] . In order to cover the 
time that passed after the search for the reviews had been finished, 
we updated 2 of the searches in MEDLINE and PubMed Central via 
PubMed. The search by Glue et al.  [26] was updated on September 
28, 2014 (from August 25, 2008 onwards) using the following 
search history:  (discontinuation [Title/Abstract] OR continuation 
[Title/Abstract]) AND (prevention [Title/Abstract]) AND (relapse 
[Title/Abstract]) AND (major depressive disorder [Title/Abstract]). 
 The search by Geddes et al.  [25] was updated on March 24, 2015 
(from July 31, 2000 onwards) using the following search history: 
 (drug Therapy [MeSH Major Topic] OR antidepr * [Title/Abstract]) 
AND (depression * [Title/Abstract] OR depressive-disorder [Title/
Abstract] OR dysthymi * [Title/Abstract]) AND (maintenance * [Ti-
tle/Abstract] OR maintain * [Title/Abstract] OR long-term [Title/
Abstract] OR continu * [Title/Abstract] OR preventive [Title/Ab-
stract]) AND (randomized controlled trial [Publication type]). 
 There were no language restrictions. We did not exclude gray 
literature. Titles and abstracts of studies retrieved were screened, 
and all possibly relevant texts were read to judge their eligibility. 
Reference lists of eligible trials were hand-searched.
 Study Selection 
 We selected studies on patients with depressive disorders (di-
agnosed with a commonly applied diagnostic system) randomized 
to receive antidepressants or placebo for at least 3 months. Al-
though in these studies the main outcomes were psychopatholog-
ical variables, we restricted our selection process to studies report-
ing on suicides (primary outcome) and suicide attempts (second-
ary outcome) during treatment.
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 Data Collection 
 Bibliographical information, key study characteristics, such as 
sample size, age or dropouts, and outcomes (number of suicides 
and suicide attempts per arm, number of follow-ups per arm) were 
extracted into an Excel spreadsheet. All corresponding authors of 
trials that were eligible but lacked data on suicides or suicide at-
tempts were repeatedly approached by e-mail or regular mail.
 Analysis 
 In most studies neither suicides nor suicide attempts were re-
ported. Classical meta-analytic calculations, such as those based on 
estimates of odds ratios (ORs), assume at least 1 event. Not includ-
ing studies without events, however, would have resulted in an 
overestimation of the risk of suicides and suicide events. There-
fore, the main analysis was based on incidence rates. Incidences of 
suicides and suicide attempts were documented as raw numbers 
per study and calculated as events per 1,000 patient-years (inci-
dence rate). From incidence rates rate ratios and p values (mid-p 
exact) were calculated. For completeness, we also calculated sum-
mary estimates based on studies reporting at least 1 event: Peto 
ORs, as a measure of rare events  [29] , were calculated. Between-
study heterogeneity is presented as the I 2 statistic. All analyses were 
conducted using Excel, OpenEpi (www.openepi.com) and Com-
prehensive Meta-Analysis, version 2 (CMA 2). Suicide and – to a 
lesser extent – suicide attempts are hard outcomes. Thus, we did 
not assess the risk of bias.
 Additional post hoc Analysis 
 In the first of two subgroup analyses we left out 1 study that 
contributed a large number of cases. In the second analyses we re-
calculated event rates without 6 studies on pediatric samples and 
older patients. In a sensitivity analysis we adjusted the overall sui-
cide rate for dropouts.
 Results 
 Through reviews of antidepressant maintenance treat-
ment RCTs  [24–28] and through our own MEDLINE and 
PubMed Central search 807 papers were identified for 
screening after duplicates were removed. Eighty-five re-
ports were read as full text. In total, the authors had re-
ported in 65 papers on various studies of antidepressant 
maintenance trials, but 36 of these had not documented 
suicides or suicide attempts or had not provided data 
upon request. The following 29 studies were included in 
our quantitative analysis:  Blumenthal et al.  [30] , Cheung 
et al.  [31] , Doogan and Caillard  [32] , Emslie et al.  [33] , 
Feiger et al.  [34] , Goodwin et al.  [35] , Kamijima et al.  [36] , 
Kishimoto et al.  [37] , Klysner et al.  [38] , Kornstein et al. 
 [39] , Lepine et al. [40] , Licht et al.  [41] , Lustman et al.  [42] , 
McGrath et al.  [43] , Montgomery et al.  [44] , Montgomery 
and Dunbar  [45] , Old Age Depression Interest Group 
 [46] , Perahia et al.  [47] , Reynolds et al.  [48] , Robinson et 
al.  [49] , Rosenthal et al.  [50] , Rouillon et al.  [51] , Schmidt 
et al.  [52] , Shiovitz et al.  [53] , Stewart et al.  [54] , Terra and 
Montgomery  [55] , Thase et al.  [56] , Versiani et al.  [57] , 
Weihs et al.  [58] .
 Online supplementary figure 1 presents the PRISMA 
flowchart (for all online supplementary material, see 
www.karger.com/doi/10.1159/000442293).
 All included studies were published between 1989 and 
2014. The studies included 6,934 patients (4,016 in antide-
pressant arms and 2,918 patients in placebo arms, respec-
tively) and covered 5,529.06 patient-years (3,218.24 and 
2,310.82, respectively). Two thirds of patients were women 
(67.2%), and the mean age was 46.6 (SD: 10.6) years.
 Antidepressants studies included the following: ne-
fazodone (1×), sertraline (6×), fluoxetine (3×), mianserin 
(1×), citalopram (3×), clomipramine (1×), escitalopram 
(1×), duloxetine (2×), maprotiline (1×), paroxetine (1×), 
fluvoxamine (1×), mirtazapine (1×), reboxetine (1×), des-
venlafaxine (1×), bupropion (1×), dothiepin (1×), nor-
triptyline (1×), phenelzine or imipramine (1×), agomela-
tine (1×) and levomilnacipran (1×). One study  [41] had 
one citalopram and one clomipramine arm. All papers de-
scribed maintenance treatment trials of patients with ma-
jor depressive disorder, with the exception of Stewart et al. 
 [54] and Rouillon et al.  [51] , who also included patients 
with dysthymia. In almost all studies randomization took 
place  after response or remission was ascertained by the 
study authors. The exception is the trial by Blumenthal et 
al.  [30] , but in this trial no acute treatment phase preceded 
long-term treatment. Online supplementary table 1 sum-
marizes the characteristics of all studies selected.
 In total, 8 suicides and 14 suicide attempts were re-
ported in all studies combined, resulting in 1.45 suicides 
(95% CI: 0.62–2.85) and 2.76 suicide attempts (95% CI: 
1.51–4.63) per 1,000 patient-years. Seven out of 8 suicides 
and 13 out of 14 suicide attempts occurred in antidepres-
sant arms. Adjusted for years exposed, suicides were 5 
times (p = 0.102) and suicide attempts 9 times (p = 0.007) 
more likely in antidepressant arms than in placebo arms 
(see  table 1 for incidence rates and rate ratios). Six of 8 
suicides and 9 of 14 suicide attempts were reported in one 
study, that of Rouillon et al.  [51] . Events were reported in 
6 studies. All had excluded patients with bipolar disorder, 
except for the study by Doogan and Caillard  [32] , with 
roughly 5% of bipolar patients in the sample.
 In meta-analyses of studies with at least 1 event we es-
timated Peto OR to be 2.6 (0.6–11.2; p = 0.21) for suicides 
and 3.4 (1.1–11.0; p = 0.040) for suicide attempts. Hetero-
geneity among studies included in the meta-analysis was 
low (I 2 values of 0 and 4%, respectively; see forest plots in 
 fig. 1 ,  2 ).
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 Slightly more patients had dropped out from placebo 
arms than from antidepressant arms: 31.1 versus 26.7%. 
Dropouts for unknown reasons were equally distributed 
between arms: 9.9% (placebo) versus 9.6% (antidepres-
sants), respectively.
 Post hoc Analyses 
 In a sensitivity analysis adjusting for dropouts we ap-
proximated an overall rate of 1.69 suicides/1,000 patient-
years (antidepressants: 2.51, placebo: 0.51).
 After omitting the study by Rouillon et al.  [51] the esti-
mate for suicides in antidepressant arms fell to 0.82 suicides 
per 1,000 patient-years (0.09–2.95) and to zero suicides in 
placebo arms (0–1.89). Accordingly, the risk difference was 
0.82 (–0.31 to 1.95). The figures for suicide attempts were 
2.24 per 1,000 patient-years under antidepressants (0.72–
5.23) versus 0.59 (0.008–3.26), with suicide attempts in an-
tidepressant arms more likely by a factor of almost 4 at 3.83 
(0.53–91.01; statistically nonsignificant).
 In another subgroup analysis we left out 6 studies of 
pediatric and geriatric samples. There were 2.45 (0.98–
5.04) suicides per 1,000 patient-years in antidepressant 
arms and 0.50 (0.007–2.78) in placebo arms, with a rate 
ratio of 4.91 (0.76–111.4). Figures for suicide attempts in 
antidepressant versus placebo arms were 4.36 (2.25–7.61) 
versus 0.56 (0.007–3.13), with a rate ratio of 7.73 (1.34–
166.8).
 Discussion 
 This study yielded several important results. Firstly, 
only a minority of papers on randomized, long-term an-
tidepressant therapy studies contained data on suicides 
and suicide attempts. Secondly, during approximately 
5,500 patient-years suicides and suicide attempts did oc-
casionally occur: roughly 1.5 suicides among 1,000 pa-
tients per year and twice as many suicide attempts. Third-
ly, the incidence rates of suicide and suicide attempts 
were higher among patients treated with antidepressants 
than among patients randomized to placebo: suicides oc-
curred 5 times more often (statistically nonsignificant) 
and the risk of suicide attempts was 9-fold (statistically 
significant) in antidepressant arms.
 Underreporting of Events 
 Many papers on long-term treatment with antidepres-
sant did not contain information on suicides and suicide 
attempts among participants. Unfortunately, it cannot be 
assumed that no events occurred only because authors do 
not report on suicide and suicide attempts. For example, 
whereas we could not find pertinent data in the paper by 
Licht  [41] , upon request, the author kindly provided us 
with the information that in their study 3 patients had at-
tempted suicide. Accordingly, the present study is re-
stricted to studies with information on suicides and sui-
cide attempts. Similar to our experience, Fergusson et al. 
 [23] , in their meta-analysis of suicide attempts under SS-
RIs, found that less than half of all trials reported on sui-
cide attempts. They also concluded that ‘a substantial 
proportion of suicide attempts have gone unreported’. It 
is conceivable that the situation is not much different in 
our set of RCTs. However, in an investigation of discrep-
ancies between clinical study reports (as submitted to the 
European Medicines Agency, EMA) and published jour-
nal articles, Maund et al.  [59] found no underreporting of 
suicides and suicide attempts in papers with respect to 
duloxetine trials. In a similar project, Hughes et al.  [60] , 
 Table 1.  Incidences and rate ratios of suicide and suicide attempts in long-term randomized trials comparing 
antidepressants and placebo
Antidepressant Rate ratio Placebo
Suicides
Incidence per 1,000 patient-years (n = 29 studies) 2.18 [0.87 – 4.48] 0.43 [0.006 – 2.41]
Rate ratio (n = 29 studies) 5.03 [0.78 – 114.1] p = 0.102
Suicide attempts
Incidence per 1,000 patient-years (n = 25 studies) 4.34 [2.31 – 7.42] 0.48 [0.006 – 2.67]
Rate ratio (n = 25 studies) 9.02 [1.58 – 193.6] p = 0.007
 Values in square brackets are 95% CI. Rate ratios are calculated from incidence rates (conditional maximum 
likelihood estimate), two-sided p values (mid-p exact).
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on the other hand, documented underreporting of sui-
cide attempts (but not completed suicides) regarding du-
loxetine and sertraline trials.
 Incidence Rates 
 Among the studies included almost a tenth of patients 
dropped out for reasons unknown to the investigators. It 
is possible that events did occur in this subgroup and, in 
principle, that they would have changed the results. The 
rate of dropouts due to unknown reasons, however, was 
the same among patients on antidepressants and on pla-
cebo – rendering different dropout patterns unlikely.
 Even if suicides and suicide attempts did occur, statis-
tically, the number of events reported in the studies se-
lected for this review is small, making precise inferences 
difficult. They are, however, in the order of magnitude of 
epidemiological estimates of suicide prevalence in major 
depressive disorder. A 6% suicide rate over 50 years  [2, 3] 
 translates into 1.2 suicides/1,000 patient-years. In com-
parison, the summary suicide rate in our meta-analysis 
was 1.45/1,000 patient-years (0.43 under placebo and 2.18 
under antidepressants).
 In contrast, our estimate of the suicide  attempt rate is 
lower than that expected from the literature: Isometsä  [4] , 
emphasizing considerable variation among studies, con-
cluded that the lifetime prevalence of suicide attempts in 
major depressive disorder amounts to 30–40%, equal to 
6–8 attempts per 1,000 patients per year. From our stud-
ies, however, we calculated 2.76 suicide attempts per 
1,000 patient-years. Suicide attempts may be underre-
ported in the studies included. The rate of 1.45 sui-
cides/1,000 patient-years is probably an underestimation 
because, similar to other studies in this field, dropouts – 
roughly 30% of the samples – were not factored in.
 These findings are surprising in view of the concern 
that RCTs may not be appropriate in estimating suicide 
First author [Ref.], 
year
Statistics for each study  Suicides/total Peto OR and 95% CI
Peto OR lower
limit
upper
limit
z
value
p
value 
 anti-
depressant
placebo
Doogan [32], 1992 4.926 0.086 283.638 0.771 0.441 1/185 0/110
Lepine [40], 2004 4.590 0.074 284.407 0.724 0.469 1/189 0/99
Rouillon [51], 1989 2.084 0.378 11.505 0.843 0.399 5/767 1/374
2.581 0.593 11.233 1.263 0.207
Heterogeneity: I2 = 0%, d.f. = 2, p = 0.89
 Fig. 1. Forest plot of studies documenting suicide events. 
First author [Ref.], 
year
Statistics for each study Suicide attempts/total Peto OR and 95% CI
Peto OR lower
limit
upper
limit
z
value
p
value 
 anti-
depressant
placebo
Emslie [33], 2008 7.691 0.152 387.874 1.020 0.308 1/50 0/52
Kornstein [39], 2006 0.122 0.002 6.165 –1.052 0.293 0/73 1/66
Licht [41], 2013 4.439 0.364 54.137 1.168 0.243 3/41 0/18
Rouillon [51], 1989 4.473 1.107 18.081 2.102 0.036 9/767 0/374
3.417 1.059 11.024 2.056 0.040
Heterogeneity: I2 = 4%, d.f. = 3, p = 0.37
 Fig. 2. Forest plot of studies documenting suicide attempt events. 
0.01 0.1 1 10 100
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risks because they tend to exclude patients at risk for sui-
cide  [9] . Among the 29 studies in this overview, however, 
only 12 mentioned such an exclusion criterion, although 
all investigators may have tried to exclude suicidal pa-
tients to limit liability. What seems even more important 
is that, unfortunately, suicides and suicide attempts are 
exceedingly difficult to predict  [12–15] . Hence, even the 
exclusion of patients considered to be at risk is unlikely to 
result in substantial risk reductions for samples as a 
whole.
 In most meta-analyses of acute treatment RCTs, the 
numbers of events are larger than in our calculation. 
Khan et al.  [22] , for example, calculated 6.6 suicides per 
1,000 exposure years, with no statistically significant dif-
ferences in the number of suicides under antidepressants 
and under placebo. The most likely explanation is that 
acute psychopathology as a risk factor for suicide is more 
severe in acute treatment studies.
 In sum, although RCTs are different from everyday 
clinical care in several ways, the summary suicide risk es-
timate seems similar to what is known from epidemio-
logical studies. In our opinion, the unquestioned advan-
tage of RCTs over observational studies in preventing 
bias makes them the most important source for estimat-
ing suicide risk reduction under antidepressants.
 The Maprotiline Study by Rouillon et al.  [51] 
 The majority of suicides and suicide attempts in our 
analyses originated from one study  [51] . This study is im-
portant because it is by far the largest one, accounting for 
about a fifth of the data (20.6% of patient-years). There is 
no reason to treat this study differently from the others 
just because several events happened in the course of this 
drug trial. However, the study stands out in several ways: 
it is the earliest study selected, it is one of 2 studies includ-
ing patients with dysthymia, and it is the only study that 
compared the tetracyclic compound maprotiline with pla-
cebo. Maprotiline has been associated with suicide in ob-
servational studies  [61] . White et al.  [62] , analyzing US 
poison control data from more than 80,000 suicidal over-
doses, reported maprotiline as among rarely used sub-
stances (19 events) but with a particularly high fatality rate 
(‘hazard index’). This study runs counter to an earlier pa-
per by Henry and Antao  [63] from the UK that reported 
maprotiline to be safer than average in overdose. Already 
in the 1990s, however, in a Swiss study maprotiline figured 
prominently among antidepressants used for suicide  [64] . 
In our post hoc sensitivity analysis leaving out the Rouil-
lon study, rate ratios decreased, but the results weakly and 
statistically nonsignificantly favored placebo.
 No Evidence for Protective Effects of Antidepressants 
 Our result of a lack of proof regarding a protective effect 
of antidepressants on suicide or suicide attempts is in line 
with meta-analyses primarily focusing on acute treatment 
studies: none of the 8 meta-analyses of antidepressant RCTs 
known to the authors resulted in statistically significant su-
periority compared to placebo  [18–23, 65, 66] . The suicide 
event rate is low, precluding definite conclusions, but if 
there is any signal from these meta-analyses, it is that there 
may be a marginal suicide risk  increase  with antidepres-
sants. For example, Stone et al.  [65] , in their comprehensive 
FDA analysis, found a slightly higher suicide rate among 
patients with major disorders in antidepressant arms 
(5/30,707 vs. 1/14,873 in placebo arms, nonsignificant). 
However, while the comparisons in those studies tended to 
numerically favor placebo over various antidepressants, 
with the exception of Hammad et al.  [19] , only few studies 
found antidepressants to be statistically significantly infe-
rior to placebo. Fergusson et al.  [23] , in a study on suicide 
attempts, reported such an inferiority for SSRIs. Similarly, 
Carpenter et al.  [66] , analyzing the GlaxoSmithKline par-
oxetine clinical trials database, found more ‘definitive sui-
cidal behavior’ (suicides, suicide attempts and preparatory 
acts toward imminent suicidal behavior) under active med-
ication than under placebo among patients with major de-
pressive disorder: OR 6.7 (1.1–149.4), but not in other indi-
cations. It has to be borne in mind that most of the trials on 
which these meta-analyses rest are short-term studies. 
However, the focus of our analysis is on long-term studies, 
which differ in many respects, for example in the fact that 
patients are remitted at study entry. In addition, phenom-
ena such as loss of antidepressant efficacy  [67] , the develop-
ment of tolerance  [67] and withdrawal symptoms  [68] may 
be important in interpreting long-term studies.
 Based on long-term trials presented to the regulatory 
drug authority in the Netherlands as well as retrieved 
through a literature review, Storosum et al.  [24] conclud-
ed that placebos are not associated with higher risks for 
suicide or suicide attempts than antidepressants. The au-
thors, in their evaluation of the study by Versiani et al. 
 [57] , erroneously assigned 1 suicide to the active com-
pound (reboxetine) that, in fact, occurred before ran-
domization. However, this error is inconsequential with 
regard to their conclusions.
 It is unlikely that a general lack of antidepressant effi-
cacy is the reason for a possible lack of  antisuicidal effi-
cacy of antidepressants. On the contrary, 3 systematic and 
1 narrative reviews that form part of the basis of this
meta-analysis reported that antidepressants are superior 
to placebo in preventing relapses  [25–28] .
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 Limitations 
 Several limitations of our study have to be borne in 
mind. In many studies, enriched and withdrawal designs 
were chosen, which may have been an advantage for an-
tidepressants. Since this study used published articles we 
could not adjust for dropout rates on an individual level. 
While it is difficult to predict how such adjustments 
would affect the differences between antidepressants and 
placebo, it is plausible that the true event rates would be 
higher than those observed, and that we present conser-
vative estimates of suicide and suicide attempt incidence 
rates. In addition, further subgroup analyses, meta-re-
gressions or other predictor searches would have been de-
sirable, but the low number of events and the nonavail-
ability of subgroup or individual patient data precluded 
further calculations.
 We could have missed important studies, but to our 
knowledge this is the largest meta-analysis of randomized 
antidepressant long-term studies so far. Meta-analyses, 
however, often put together a heterogeneous set of studies 
but arrive at a global effect estimate  [69] . In this sense, we 
have treated antidepressants as a homogeneous group, but 
it is certainly possible that different compounds behave 
differently. At least, we found preliminary evidence that 
maprotiline may constitute a particular risk. However, in 
principle, it would be desirable to analyze data for every 
antidepressant specifically (as has been done, for example, 
for paroxetine  [66] or for venlafaxine and citalopram 
 [21] ). For the time being, however, there is no viable alter-
native to meta-analyzing all the data that are available.
 Conclusions 
 In conclusion, we found no evidence from random-
ized trials of long-term antidepressant treatment that, as 
a group, antidepressants prevent suicide or suicide at-
tempts among patients with major depressive disorder. 
The rate of patients killing themselves during the studies 
under investigation is in the order of magnitude expected 
from epidemiological models. Doctors and patients 
should be aware of this finding and should not rely solely 
on antidepressants in dealing with suicidality. Close clin-
ical monitoring of patients at risk for suicide is impera-
tive. A psychopharmacological option in the prevention 
of suicide is lithium  [70] .
 We cannot exclude that antidepressants carry a  higher 
risk of suicide or suicide attempts than placebo. It is of 
paramount importance for future research that all papers 
reporting on randomized antidepressant studies contain 
information on suicides and suicide attempts.
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